Gallbladder Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against gallbladder cancer and guarantee the finest results for our customers all over the world.

Gallbladder Cancer

Gallbladder cancer is a relatively rare cancer. It is thought to be associated with the building up of gallstones and may also cause gallbladder calcification, a situation known as porcelain gall bladder, which is also rare. Some studies show that patients with porcelain gallbladder have a high risk of developing gallbladder cancer, but other studies have questioned this. It has a unique geographical distribution in Central and Eastern Europe, Japan and northern India, Central and South America. It is also common among certain ethnic groups such as Hispanic and Native American Indians. If diagnosed early, it can be cured by resection of the gallbladder, part of the liver, and the associated lymph nodes. It is mostly found after abdominal pain, jaundice and vomiting and other symptoms, and has already spread to the liver and other organs. If cancer is found after symptoms have started to occur, the 5-year survival rate is close to 3% and the prospect is not good for recovery.

Therapeutic Vaccines for Gallbladder Cancer

Gallbladder Cancer - Creative Biolabs Immunotherapy holds good promise in non-responding cancers treated by conventional chemotherapeutic agents. Among various therapies, dendritic cell therapy is growing at rapid pace due to its acceptable rationale. It has been utilized in treating successfully resected stage III (T2, N1, M0) gallbladder cancer in some of the patients. Immunotherapy, especially dendritic cell therapy is expected to give good results in stage IV cancer. Most of the trials are conducted during this stage of disease where no therapy can be a guarantee of cure. A 48 years old lady treated with this therapy is free of metastasis with ten doses of autologous dendritic cell vaccine constructed by utilizing resected tumor lysate antigen. She has received ten doses of therapy in 14 months of her treatment. This therapy has proven to be safe and without apparent side effects. The positive clinical response obtained supports that autologous dendritic cell-based immunotherapy is a promising therapeutic approach for refractory gallbladder cancers. The diagnosis of gallbladder cancer should not be approached with a fatalistic attitude, as appropriate workup, extended resection and newer approaches including dendritic cell therapy can extend quality of life with chances of cure.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the gallbladder cancer vaccines. If you are interested in our services, please contact us for more details.

Reference

  1. Khan, JA. (2006). “Successful immunological treatment of gallbladder cancer in India--case report.” J Zhejiang Univ Sci B 7(9), 719-724.

Our services are for research use only. We do not provide services directly to individuals.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-466-5530
Fax: 1-631-207-8356
Email: Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828 Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket